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Taking into account the complexity and limitations of clinical assessment in hypertrophic cardiomyopathy (HCM), imaging techniques play an
essential role in the evaluation of patients with this disease. Thus, in HCM patients, imaging provides solutions for most clinical needs, from
diagnosis to prognosis and risk stratification, from anatomical and functional assessment to ischaemia detection, from metabolic evaluation
to monitoring of treatment modalities, from staging and clinical profiles to follow-up, and from family screening and preclinical diagnosis to
differential diagnosis. Accordingly, a multimodality imaging (MMI) approach (including echocardiography, cardiac magnetic resonance,
cardiac computed tomography, and cardiac nuclear imaging) is encouraged in the assessment of these patients. The choice of which tech-
nique to use should be based on a broad perspective and expert knowledge of what each technique has to offer, including its specific advan-
tages and disadvantages. Experts in different imaging techniques should collaborate and the different methods should be seen as
complementary, not as competitors. Each test must be selected in an integrated and rational way in order to provide clear answers to spe-
cific clinical questions and problems, trying to avoid redundant and duplicated information, taking into account its availability, benefits, risks,
and cost.
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Introduction
Definitions, epidemiology, and pathology
To clinical cardiologists and cardiac imagers, the expression ‘left ven-
tricular hypertrophy’ (LVH) describes a specific phenotype of
increased wall thickness (WT) and/or LV mass. However, the hyper-
trophic phenotype is a common final pathway of multiple different
genetic and acquired conditions, including abnormal load conditions,
sarcomeric abnormalities (hyperplasia, hypertrophy, and disarray),
and intracellular and interstitial accumulation of different materials
(fibrosis, infiltration, etc.).1
Sarcomeric hypertrophic cardiomyopathy (HCM) is the major
cause of unexplained LVH. It is a primary myocardial disease,
defined by inappropriate LV hypertrophy, disproportionate to
the degree of LV loading conditions, occurring in the absence of
another cardiac or systemic disease, metabolic or multiorgan syn-
drome associated with LVH. HCM also affects other cardiac struc-
tures such as the mitral valve apparatus, the small coronary
arteries, and the cardiac interstitium.2,3
HCMisthemostcommongeneticheartdisease,phenotypicallyaffect-
ing at least 0.2%(1 : 500)of general adultpopulationsofdifferent genders,
ethnicities, and races.4,5 It usually results from mutations in genes encod-
ing sarcomeric proteins, transmitted in an autosomal dominant inherited
pattern, with incomplete penetrance and variable expression.6,7
The classical clinical diagnosis of HCM is based on unexplained
LVH by imaging techniques, though in the last decades the role of
genetic diagnosis has increased.2,3,6 – 12
The typical pathological findings of the disease are myocyte hyper-
trophy and hyperplasia, myocyte disarray, small vessel disease, and fibro-
sis.13,14Twomajor typesoffibrosisareseen: interstitialfibrosis (increased
collagen, without evidence of cardiomyocyte loss) and replacement
fibrosis (increased collagen with evidence of cardiomyocyte loss).15–18
Natural history and clinical course
HCM is often a benign condition, asymptomatic, and with normal life
expectancy,19 but some patients have adverse clinical profiles and
serious complications. Although symptoms can occur at any age,
theyare more common between the ages of 20 and 40 and later pres-
entation is generally associated with less severe forms of the disease.
Sudden cardiac death (SCD) is the most devastating presentation,
and HCM represents the most frequent cause of SCD in the young
and in athletes under 35 years old in countries without systematic
sport screening programmes.20
Heart failure (HF) and atrial fibrillation (AF), especially when cardi-
oembolic events occur, are other clinical presentation modalities and
represent important causes of disability in middle and older age
groups. Intraventricular obstruction is a common associated finding
that often alters the natural history of HCM. The overall mortality of
untreated HCM patients is about 1.3% per year (0.8% in the general
population), but the absolute individual risk is highly variable.21
While some HCM topics (SCD and intraventricular obstruction)
have been extensively studied, others (myocardial ischaemia and
the natural history of the disease) remain relatively ‘forgotten’ and
are research priorities in disease investigation.22
Determinants of HF, arrhythmias,
and myocardial ischaemia
HF, arrhythmias, and ischaemia represent some of the major conse-
quences of HCM.12
Heart failure
HF in HCM may result from LV systolic and/or diastolic dysfunction
and from intraventricular obstruction. All phases of diastole are
affected in HCM. Abnormal relaxation occurs as a consequence of
disturbed calcium kinetics, ischaemia, LVH, and fibrosis. Abnormal
stiffness and compliance result from abnormal LV geometry,
impaired sarcomeric properties, myocyte disarray, and fibrosis.23–26
In some patients, during the natural historyof the disease, bursts of
silent, asymptomatic microvascular ischaemia lead to progressive cell
death, with replacement fibrosis that predicts LV adverse remodel-
ling with evolution to LV systolic dysfunction.27,28
In the advanced stages of LV systolic dysfunction,29 additional fea-
tures such as functional mitral regurgitation (MR), pulmonary arterial
hypertension (PHT), and right ventricular (RV) systolic dysfunction
may also contribute to HF symptoms and prognosis.
Arrhythmias
The arrhythmogenic substrate for ventricular arrhythmias in HCM is
multifactorial. Myocyte disarray and fibrosis play important roles,30
but microvascular dysfunction and ischaemia can also be determi-
nants. In the advanced stages, ventricular arrhythmias are also asso-
ciated with LV systolic dysfunction.29
AF results from left atrial (LA) dilation and dysfunction31 partially
causedbyhaemodynamic factors,mainlyLVdiastolicdysfunctionandMR.
Myocardial ischaemia
Myocardial ischaemia in HCM is mainly due to increased oxygen
demand (LVH, diastolic dysfunction, and obstruction) and to
Table 1 Imaging in HCM: imaging solutions for clinical
needs
1. Diagnosis
2. Anatomy: confirmation and characterization of LVH, mitral valve
apparatus, intraventricular obstruction, and tissue
characterization
3. Myocardial function: systolic and diastolic function
4. Ischaemia (macro and microvascular)—functional and anatomical
imaging
5. Metabolism, myocardial receptors, and innervation
6. Monitoring of different treatment modalities: medical treatment,
surgery, ASA, and pacing
7. Staging and natural history: G+, P2, non-hypertrophic stage and
early phenotype, classical phenotype, adverse remodelling, and
overt dysfunction
8. Clinical profiles: SCD profile, HF profile, AF—stroke profile
9. Follow-up
10. Prognosis/risk stratification
11. Family screening and preclinical diagnosis
12. Differential diagnoses with phenocopies
G+, genotype positive; P2, phenotype negative; ASA, alcohol septal ablation.
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decreased perfusion (small vessel disease, abnormal vascular re-
sponse, increased resistance, and myocardial bridging).27,30–33
Among these mechanisms, the major cause of myocardial ischaemia
in HCM is arteriolar remodelling with coronary microvascular dys-
function. Recent studies showed an association between ischaemia,
fibrosis, and LV remodelling, providing support that microvascular
dysfunction is responsible for myocardial ischaemia-mediated
myocyte death, and thus replacement fibrosis.34,35
The role of imaging in HCM: diagnosis,
clinical profiles, and follow-up
On account of the complexity and the limitations of clinical assess-
ment in HCM, multimodality imaging (MMI) techniques—
echocardiography (echo), cardiac magnetic resonance (CMR),
cardiac computed tomography (CCT), and cardiac nuclear
imaging (CNI)—provide a broad spectrum of information, fromdiag-
nosis to clinical management of the major clinical profiles of the
disease (SCD, HF, and AF/stroke;36 Tables 1 and 2; Figure 1).
Patients with HCM usually require lifelong follow-up. Though the
approach remains individualized we suggest that transthoracic echo
(TTE) should be performed every 1–2 years in clinically stable
patients (Table 3) and CMR at least once after the diagnosis of
HCM (Table 4) if local resources and expertise permit, being
repeated during follow-up when clinically indicated.
The role of imaging in HCM: preventive
and therapeutic strategies
Imaging plays an essential role in the estimation of risk of SCD and in
the monitoring of therapy in HCM patients.
The risk of SCD in HCM is 1% per year and implantable cardio-
verter defibrillator (ICD) therapy is effective in its prevention.
In the classical strategy,37 the risk increases proportionally to the
numberoffiverisk factors (oneprovidedby imaging), but thenegative
and positive predictive values (NPV and PPV) of this strategy are low.
In a new, recently validated individualized model,38 of the eight pre-
specified predictor variables related to SCD risk at 5 years assessed
at baseline evaluation, half were derived from echocardiography,
strengthening the crucial role of imaging in this topic.
Additional future prediction of SCD may emerge from assess-
ment of ischaemia and fibrosis. The presence of late gadolinium
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Resolution and contrast to noise ratio of the
different imaging techniques
Echo CMR CCT CNI
Spatial resolution +++a +++ ++++ ++
Temporal resolution ++++ +++ ++ +
Contrast to noise ratio ++ ++++ +++ ++
CMR, cardiac magnetic resonance; CCT, cardiac computed tomography; Echo,
echocardiography; CNI, cardiac nuclear imaging.
aThe absolute spatial resolution of ultrasound is excellent, but in the clinical setting it
is affected by probe frequencyand depth (penetrance), as well as by patient’s factors.
Figure 1 Imaging phenotypes (LVH, LVOTO, fibrosis, microvascular ischaemia, and myocardial bridging) and clinical profiles/phenotypes (SCD,
HF, AF/stroke, and angina) of HCM. LVH: an important determinant (++) of SCD, HF, and AF in HCM, may be associated with angina (+). LVOTO:
an important determinant (++) of HF, AF, and angina in HCM; its role in SCD is still in research [+ (?)]. Fibrosis: an important determinant of HF
(++), it is also related (+) to AF in HCM; its precise role in SCD is still in investigation [+ (?)]; no role in angina. Microvascular ischaemia (more
common in subendocardial regions of hypertrophied walls) is thought to be a strong determinant of angina, SCD, and HF (++) and is also
related (+) to AF. Myocardial bridging is a common feature of HCM. It may cause angina and anecdotical cases have linked it to SCD. It has no
clear role in HF and AF. LVOTO, left ventricular outflow tract obstruction.
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enhancement (LGE) on CMR has recently been linked with SCD,
but its clear role in risk stratification is yet to be defined
(Table 5).39,40
The assessment of anatomy
Imaging hypertrophy
Imaging plays a major role in the assessment of hypertrophy in HCM,
contributing to its diagnosis, assessment of regional distribution, and
quantification, with relevant prognostic implications.
LVH is a dynamic process in HCM: it is rare in childhood (only seen
in very severe disease and in phenocopies), during adolescence the
beginning and growth of LVH often occurs, and in adults the rule is
stabilization, often with mild regression of WT. In the presence of
‘paradoxical reverse remodelling’ in adults (increase of LVH), an
additional cause of LVH [obesity, sports, hypertension (HT), aortic
stenosis, and infiltration] should be excluded.
In HCM, LVH is often segmental, with non-contiguous patterns of
increased WT. It may affect from only one to all LV segments,41 but
the basal interventricular septum (IVS) is the most common region
of hypertrophy.
As hypertrophy can be found at any location, its presence, distribu-
tion, andseverity shouldbedocumentedusing acommonstandardized
protocol forall imaging techniques.MeasurementsofLVWTshouldbe
performed at end-diastole and are more accurate in short-axis views
(though all available views should be used21). All LV segments should
be examined from base to apex.42
Echocardiography
TTE is the initial imaging modality for the evaluation of LVH2
(Figure 2). The following two-dimensional (2D) echo diagnostic cri-
teria are used:
(i) unexplained maximal WT .15 mm (or higher than 2 standard
deviation (SD) for age, gender, and height) in any myocardial
segment, or
Table 3 What an echo report in HCM should include
Left ventricle
findings
–Wall thickness
Involved segments and maximal thickness (consider
contrast echo); septal: posterior wall ratio
Consider asymmetric septal hypertrophy and septal
morphology (reverse curvature, neutral, and
sigmoid), concentric, midventricular, and apical
variants
Consider RV hypertrophy
–Left ventricle cavity size
-Systolic function
EF, fractional shortening, and indexed stroke volume
also consider s′ (DMI) and longitudinal strain
(2D-STE)
–Diastolic function
E/e′ lateral, Ar-A, LA volume index, sPAP
–Left ventricular outflow tract obstruction
Mechanism, provocable vs. fixed obstruction
Level of obstruction (consider midventricular
obstruction)
Presence and severity at rest and under provocative
manoeuvres—Valsalva, standing (obstructive,
provocable obstructive or non-obstructive
HCM)
Mitral valve
findings
Mitral SAM and its characterization (septal contact
and duration)
Leaflets, chordae and PM abnormalities
Exclude concurrent organic disease
Presence, mechanism, and severity of MR
Aortic valve
findings
Leaflet sclerosis
Mid-systolic partial valve closure
EF, ejection fraction; DMI, Doppler myocardial imaging; HCM, hypertrophic
cardiomyopathy; SAM, systolic anterior motion of the mitral valve; LA, left atria; PAP,
pulmonary arterial systolic pressure; STE, speckle tracking echocardiography; PM,
papillary muscles.
Table 4 What a CMR report in HCM should include
1. Left ventricle volumes, mass, and ejection fraction
2. Location, type, distribution of hypertrophy, maximal WT and
diastolic wall thickness to volume ratio
Septum, apex, and midventricular
Concentric, focal, intermediate, diffuse
3. Degree of asymmetry
Compare the thickest with thinnest wall (e.g. septum and
lateral wall)
4. LVOT or mid-cavity obstruction
Provide peak velocity/gradient
5. LGE
Presence/absence
Pattern (RV insertion points and intramural) and extension (%)
6. Evidence of MR
7. Mitral valve apparatus (leaflets, chordae, PMs)
Description and its relation to obstruction /MR
HCM, hypertrophic cardiomyopathy; CMR, cardiac magnetic resonance; LVOT, left
ventricular outflow tract; RV, right ventricle; LGE, late gadolinuim enhancement.
Table 5 EACVI expert consensus key points on MMI in
HCM
1. Imaging tests play an essential role in HCM, and a MMI approach is
encouraged in the assessment of this disease.
2. Experts in different imaging techniques must collaborate and the
different imaging methods must be seen as complementary rather
than competitive. Each test must be selected in an integrated and
rational way, providing answers to specific clinical questions and
problems, trying to avoid redundant and duplicated information,
always taking into account its availability, benefits, risks, and cost.
3. Echocardiography is recommended in all HCM patients
and should be performed every 1–2 years in clinically
stable patients.
4. CMR should be considered in all HCM patients. It should be
performed at least once (at the initial evaluation) if local resources
and expertise permit, and may be repeated according to potential
changes in the clinical status, in order to answer to specific clinical
questions and problems.
5. Cardiac CT and nuclear imaging techniques have more limited
indications in this disease and are only indicated in specific clinical
situations.
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(ii) Asymmetric septal hypertrophy (ASH): septal/posterior WT
ratio of .1.3 in normotensive patients (.1.5 in HT).
In first-degree relatives of patients with an established diagnosis
of HCM, lower cut-off values are used, and a WT of ≥13 mm in
the anterior septum or posterior wall suggests the diagnosis.43
The distribution of hypertrophy in HCM is classically assessed by
2D echo and several time-honoured classifications have been pro-
posed. Though attractive by their simplicity, its clinical implications
are limited.44– 48
Asymmetric septal hypertrophy (ASH) is common, but non-
specific of HCM (early HT, RV hypertrophy, and inferior myocardial
infarction with previous LVH can present with ASH).
To diagnose other localized forms of LVH, the addition of contrast
echocardiographic agents to induce LV cavity opacification is useful
when echo images are suboptimal (specifically in the lateral or
antero-lateral LV wall and in the apex).
IVS morphology has also been correlated with the probability of a
positive genetic test for sarcomeric mutations: accordingly, a reverse
IVS is associated with a high probability of a positive genetic test,
apical or neutral IVS with a moderate probability, and a ‘sigmoid’
IVS with a low probability of a positive test.7
Correct orientation and beam alignment is essential to avoid fore-
shortened or oblique sections that overestimate WT. Measurements
should be done at end-diastole and are more accurate in short-axis
views using bidimensional echo at the mitral valve, papillary
muscles (PMs), and apical levels. Though all available views may be
used to confirm WT, measurements in apical views overestimate
WT because of the constraints of lateral resolution.
Additionally, as the inclusion of RV structures (elements of the tri-
cuspid valve apparatus, RV moderator band, crista supraventricularis,
and RV trabeculations) in measurements often leads to false septal
hypertrophy, the identification of these structures and its exclusion
from measurements must be systematically performed.
3D echo might provide more accurate information on LV geom-
etry and mass49 and also on left ventricular outflow tract (LVOT)
morphology, specifically in the assessment of the aorto-septal
angle, a marker of inducible left ventricular outflow tract obstruction
(LVOTO).50 However, 3D echo is still underutilized in HCM and its
incremental value remains largely unknown.51
RV WT should also be measured. (Normal RV WT is ,5 mm in
subcostal or parasternal long-axis views at end-diastole, at the level
of the tricuspid chordae2). Inclusion of epicardial fat in the measure-
ment of RV free WT is a common cause of false RVH.
Cardiac magnetic resonance
CMR should be considered in the initial evaluation of all patients with
HCM if local resources and expertise permit.19 It provides complete
coverage of both ventricles and is the gold standard for the assess-
ment of WT28,52– 54 and chamber volumes, with high spatial and tem-
poral resolution, in any plane and without ionizing radiation2,36
(Figure 3).
Cine CMR using steady-state free precession (SSFP) pulse
sequences is recommended and produces sharp contrast between
Figure 2 Echocardiography and LVH. Top: (A) apical 4C view, diffuse massive LVH, an ICD lead may be seen in the right chambers; (B) short-axis
view, PMs level; (C) parasternal long-axis view, with ASH. Bottom: Apical HCM. (D) Apical four-chamber view, telediastolic frame, apical thickness
15 mm. (E) Apical HCM, four-chamber view, no contrast, ace of spade configuration. (F ) Apical HCM, four-chamber view, left ventricular cavity
opacification with contrast.
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the bright blood pool and the dark myocardium with clear delinea-
tion of the epicardial and endocardial borders.
CMR detects LVH more frequently than echo (6% in one recent
series53) and shows that echo underestimates maximal diastolic
WT measurements by 20%.52– 54
The diastolic WT to volume ratio by CMR (which corresponds to
the echo parameter relative WT) has been proposed as an accurate
way to differentiate physiological from pathological hypertrophy
(lower than 0.15 mm m2/mL in physiological LVH).55
The extension of LVH may also be defined with CMR as focal (1–2
hypertrophic segments, present in .10% of HCM patients), inter-
mediate (3–7 segments, seen in .30%), and diffuse LVH (8–16
hypertrophic segments, observed in .50% of patients). In the pres-
ence of focal hypertrophy, LV mass is usually not increased.41
Finally, CMR is also able to identify the RV structures that can be
incorrectly included in the echocardiographic measurements of
septal thickness.
Cardiac CT
CCT may be used to assess anatomy in the presence of suboptimal
echocardiographic images and of contraindications to CMR. (CCT
has higher spatial resolution than CMR, but its routine use is
limited by radiation exposure.)
Cardiac nuclear imaging
Becauseof lowspatial resolutionand radiation, its use is not indicated.
The mitral valve and its apparatus
More than 50% of HCM patients have abnormal mitral leaflets, and
more than25% showabnormalitiesof the chordae and PMs (Figure 4).
These abnormalities include leaflets elongation with excessive
tissue,56 dysplasia and prolapse, and chordal elongation, laxity and
hypermobility. In some patients, leaflets and chordae length are
increased in absolute terms (length exceeding age, sex, and body
size matched controls by 2 SDs), as a primary phenotypic expression
of HCM; in other patients, leaflets and chordae are normal sized but
relatively too large to the small LV cavity and LVOT size, also contrib-
uting to obstruction.
PM abnormalities include hypertrophy, bifidity, anterior/apical dis-
placement, and direct insertion into the anterior mitral valve leaflet.
Echocardiography
A systematic assessment of all the components of the mitral valve
apparatus is required in HCM.
Systolic anterior motion (SAM) of the mitral valve, an important
determinant in LVOTO in HCM, is common but non-specific (alter-
native causes, with or without LVH, are hypovolaemia, inotropic
drugs use, normal or HT individuals with small ventricles, and
Figure 3 CMR and LVH. Cine CMR-SSFP in different HCM patients. Top: (A) Basal short-axis view, LVH only sparing the lateral wall. (B) Three-
chamber view, midventricular hypertrophy of the medial segments of the posterior wall and anterior IVS. Bottom: (C) short-axis view, LVH localized
in the transition between the anterior wall and the anterior septum (18 mm), undetected by echocardiography. (D) Three-chamber view, systole.
Courtesy: Ferreira A, MD and Marques H, MD, Multimodality Cardiac Imaging Department, Hospital da Luz, Lisbon, Portugal.
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mitral valve surgical repair36). Its presence and severity is better
documented with M-mode (high temporal resolution), being incom-
plete if it does not touch the IVS, mild if the mitral-septal contact
occurs in late systole and for ,10% of systole, and severe if it
starts at mid-systole, occupying .30% of its duration.57
The anterior leaflet elongation58 and its increased mobility impair
adequate leaflet coaptation, resulting in SAM-related, eccentric pos-
terior and lateral MR (a central or anterior jet often indicates the
presence of organic disease).
The quantification of MR should be performed according to the
published recommendations59 and its dynamic component evaluated
using exercise echo (EE).60
When 2D and TTE images are insufficient to assess mitral valve
morphology and function, 3D echo and transoesophageal echo
(TOE) may be considered.
Cardiac magnetic resonance
CMR can image the mitral valve apparatus and quantify MR, and may
be determinant in the selection of the invasive gradient reduction
therapy procedure.61
The anatomical information provided by cine CMRcan be compar-
able to or better than that of echo, but imaging slices in CMR are rela-
tively thick, potentially leading to partial volume effects and data are
averaged over several cardiac cycles, so that small structures are not
well visualized. CMR protocols in HCM should include the assess-
ment of the mitral valve, with slices positioned perpendicular to
the valve plane (through-plane) along with in-plane views of the
valve orifice. Velocity-encoded CMR imaging is added for assessment
of flowabnormalities. The mitral valve leaflet length by CMR hasbeen
shown to be an important determinant of LVOTO.56
Cardiac CT
CCT is seldom used in this setting, only when echocardiographic
images (including contrast and TOE) are suboptimal and CMR is
contraindicated.62
Cardiac nuclear imaging
CNI has no role in this setting in HCM.
Intraventricular obstruction
Obstruction may occur at the LVOT (Figure 5) or at the midventricu-
lar level (Figure 6).
LVOTO is defined by the presence of a peak gradient higher than
30 mmHg at rest or after provocative manoeuvres (Valsalva, stand-
ing, and exercise).3
LVOTOat rest is present in aboutone-thirdofHCMpatients and is
an independent determinant of adverse prognosis.63 In another
Figure4 MMI and the mitral valve apparatus. Top: (A and B) long-axis parasternal view—dysplastic mitral valve leaflets. Bottom: (C) 2D echocar-
diography, apical two/three-chamber view—elongated, dysplastic, hypermobile chordae. (D) Cine CMR (SSFP), four-chamber view, apical insertion
of a PM contributing to the intraventricular obstruction.
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one-third of HCM patients, LVOTO is only seen after provocative
manoeuvres.64 The most widely accepted explanation for LVOTO
is the presence of IVS hypertrophy and narrowing of the LVOT
with mitral SAM towards the IVS.65 According to loading conditions
and contractility status, LVOTO shows unpredictable and spontan-
eous variability,66 and even a ‘paradoxical’ gradient reduction with
exercise was recently described.60
Echocardiography
The echo report should provide the description, mechanism, and the
anatomical level of obstruction.
LVOTO usually causes aortic valve mid-systolic partial closure and
mitral SAM with septal contact and turbulent colour Doppler flow in
the LVOT. The severity of obstruction is quantified with continuous
wave (CW) Doppler, from the apical view. The typical morphological
appearance of the Doppler envelope in LVOTO is a ‘dagger-shaped’
and late-peaking curve. Care should be taken to avoid contamination
with the MR jet, overestimating the obstruction. The assessment should
be performed under resting conditions and after provocative man-
oeuvres (Valsalva manoeuvre, standing, and exercise; Figure 7). The use
of nitrates and of dobutamine as provocative drugs is not indicated
(the use of dobutamine may lead to confounding results because of
the induction of non-physiological intraventricular gradients, caused by
the pharmacological effects of this drug and not by the disease itself).67
Exercise echocardiography (EE) using treadmill exercise is an im-
portant technique in the detection of inducible obstruction in
HCM.64,68 The assessment should be taken during exercise and at
the beginning of the recovery period, when preload decreases, in-
creasing LVOTO69 (Figure 8). EE is feasible, safe, and physiological
(mimicking real-life load conditions), allowing the clinical integration
of obstruction, exercise . . . exercise tolerance, symptoms, blood
pressure, and arrhythmias, and may provide incremental information
Figure5 Echocardiographic assessment of left ventricularoutflowtract obstruction. (A) 2D-echo parasternal long-axis viewwith systolic anterior
motion of the anterior mitral valve leaflet. (B) Systolic anterior motion (SAM) of the anterior mitral valve leaflet in M-mode. (C) M-mode colour
Doppler flow imaging of the localization of the obstruction (colour aliasing in SAM). (D) 2D echocardiography with colour Doppler flow imaging
of the localization of the obstruction in the LVOT. Note the SAM-related MR. (E) M- mode partial mid-systolic closure of the aortic valve. (F)
CW Doppler recording of the obstruction with a maximal peak gradient of 75 mmHg. Note the “dagger-shaped” envelope with late systolic peak.
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over other provocative manoeuvres in such an unpredictable and
heterogeneous disease.
EE should be performed in symptomatic patients if bedside man-
oeuvres fail to induce LVOTO higherorequal to50 mmHg; in asymp-
tomaticpatients, itmay beconsideredwhen the presenceof anLVOT
gradient is relevant to lifestyle advice and decisions on medical
treatment.19
Additionally, EE provocable gradients can be useful in clinical prac-
tice to support the diagnosis of HCM in individuals with familial
history of HCM and doubtful/borderline but non-diagnostic TTE.
Midventricular obstruction is due to midventricular hypertrophy or
anomalous PM insertion. The LV chamber is typically ‘hourglass
shaped’ and apical aneurysms are common. Colour Doppler often
shows aliasing in the sequestered apical area and a paradoxical
apex to base diastolic gradient. Contrast echo may also be important
in these patients.
Cardiac magnetic resonance
CMR allows for a precise depiction of the morphology of the LV,
LVOT, and mitral valve, and thus of the location and cause of obstruc-
tion. Complex interactions between LV shape and LVOTO can be
identified with cine CMR. In addition, phase-contrast velocity-
encoded CMR allows visualization and quantification of flow. In
the LVOTO, the turbulence can be readily depicted with
velocity-encoded CMR in imaging planes aligned with the LVOT.
Accurate quantification requires acquisition of additional imaging
planes perpendicular to the maximal velocity jet. CMR during phys-
ical exercise is feasible, but rarely performed.
Cardiac CT
Since CCT is a cross-sectional technique, all cardiac structures may
theoretically be studied, as well as hypertrophy, the mitral apparatus,
and obstruction may be reliably assessed and quantified.70–73
However, these additional pieces of information must be only con-
sidered as ‘add-ons’, when performing CCT with different indications
[to assess coronary artery disease (CAD)] or when echocardio-
graphic images are suboptimal and CMR is contraindicated.
Cardiac nuclear imaging
The use of CNI is limited to the detection of a hyperdynamic LV with
cavity obliteration in gated blood pool radionuclide angiography
(RA).
Figure6 MMI—midventricular obstruction with a small apical aneurysm. (A) 2D TTE, apical view—paradoxical colour aliasing in the apex. (B and
C) Contrast echocardiography showing an ‘hourglass’ chamber. Courtesy: Dr A. Hagendorff, Leipzig, Germany. (D) CWD—paradoxical apical–
basal diastolic gradient, peak 24 mmHg. (E) Cine CMR-SSFP, diastole, four-chamber view. (F ) Cine CMR-SSFP, systole, four-chamber view. (G)
CMR-LGE in the apical aneurysm, four-chamber view. (H ) CMR-LGE in the apical aneurysm, two-chamber view. Courtesy: Ferreira A, MD,
Marques H, MD and Gonc¸aves P, MD, PhD, Hospital da Luz, Lisbon, Portugal.
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Tissue characterization
CMR is the most important technique in tissue characterization,
though echo and CNI may also provide indirect information.74– 76
Cardiac magnetic resonance
The method of LGE CMR is based on the principle that tissues with an
expanded extracellular space provide a larger distribution volume for
the conventional CMR contrast agents, which are extravascular and
extracellular. After administration, these agents are distributed in
the extracellular myocardial space before being gradually cleared.
Several minutes later (5–20 min, depending on the contrast agent
dose, metabolism, and other factors), differences between tissue
with normal and expanded extracellular volumes are largest and
LGE acquisition is performed. Because CMR contrast agents have
T1 shortening properties, imaging uses a strongly T1-sensitive pulse
sequence. Current LGE methods provide a very high spatial
resolution (in plane 1 mm or less) and provide a very high contrast
to noise ratio, allowing to delineate small amounts of myocardial
fibrosis.
In HCM patients, fibrosis is progressive77 and frequent (found in
about two-thirds of patients).35,39,40 Two major distribution patterns
of LGE are seen:78 intramural LGE, within the hypertrophied seg-
ments, thought to correspond to replacement fibrosis; and RV inser-
tion points LGE,15 thought to correspond to interstitial fibrosis and/
or myocyte disarray (Figure 9). However, the histological basis of LGE
in HCM has been difficult to assess because of the lack of a spontan-
eous HCM animal model.79
Moreover, the pathophysiological consequences of the different
types of fibrosis and its prognostic role are also debated:17,18,76,80–82
myocardial fibrosis is associated with a strong and independent
adverse outcome in HCM patients17,39,40,83 and in one early
study,39 LGE was the strongest predictor of cardiac mortality and
SCD. However, to be incorporated into routine clinical and
Figure 7 Provocative manoeuvres in an 18-year-old male with non-obstructive HCM at rest (LVOT peak gradient in the left lateral decubitus
21 mmHg, mild MR). Left—Valsalva manoeuvre; top: CWD, LVOT peak gradient 81 mmHg; bottom: 2D colour Doppler flow aliasing in the
LVOT and SAM-related eccentric MR, at least moderate. Right: standing in the upright position; top: CWD, LVOT peak gradient 94 mmHg;
bottom: 2D colour Doppler, turbulence in the LVOT and SAM-related eccentric MR, moderate to severe.
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prognostic evaluation, quantification of CMR-LGE is needed. In a
recent study,84 a linear relation was found between the amount of
LGE (in terms of percentage of myocardial mass) and SCD risk,
evenafteradjustment forLVejection fraction (LVEF) and additionally,
a continuous relation was found between the percentage of LGE and
the future development of systolic dysfunction.84 However, these
results were not confirmed in a concomitant work from a different
group:85 though the amount of fibrosis was, in this study, a strong
univariable predictor of SCD, this effect was not maintained after
adjusting it for LVEF. Remarkably, both studies agree that it is the
total amount of LGE, not its pattern or location that have impact in
outcomes.
Though LGE-CMR has been considered the gold standard for non-
invasive assessment of fibrosis, its usefulness is still under research
because it underestimates fibrosis (specially the diffuse interstitial
type86) and only performs an indirect assessment of fibrosis.
New promising methods include T1 mapping, an emerging tool
that allows direct signal quantification on a standardized scale
for each myocardial voxel, overcoming some of the limitations
of LGE, permitting an estimate of the extracellular volume fraction,
accurately detecting interstitial fibrosis underestimated by
LGE-CMR (Figure 10). Evidence for T1 mapping in HCM is currently
limited and a field of intensive research.87,88
Finally, techniques to image disarray, like CMR diffusion tensor
imaging (or ultrasound-based shear-wave imaging), are not yet
ready for clinical use.89
Cardiac CT
CCT may be rarely used for the evaluation of fibrosis (only if CMR is
contraindicated). In this setting, a second delayed scan is needed to
evaluate a potential late enhancement in fibrotic areas. The principle
is comparable to CMR, as the iodinated contrast agent of CCT
accumulates in areas without regular structure of the myocytes, for
example in fibrosis, leading to higher density levels.90
The additional radiation of this second scan limits its clinical
applicability, in particular in follow-up studies (Table 6).
The assessment of cardiac function
The assessment of ventricular function by MMI is essential in patients
with HCM.
LV systolic function
Echocardiography
The echo Doppler evaluation of LV systolic function in HCM
patients (fractional shortening (FS), LV ejection fraction (EF), and
stroke volume) has traditionally been assessed by M-mode, 2D,
and pulsed wave Doppler (PWD), using volumetric and flow
methods (Figure 11).
The limitations of LVEF are well known when LVH is present.91 EF,
mostly reflecting radial wall thickening, is often preserved in HCM,
compensating the reduced longitudinal function seen in this
disease. Moreover, the normal/supernormal global EF of HCM
Figure 8 Treadmill EE in a patient with non-obstructive HCM at rest but with provocable obstruction. LVOT gradient (in mmHg): left—rest,
standing: 18; center—peak exercise: 66; right—initial recovery: 94.
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Figure9 Major distribution patterns of LGE in HCM and its histological correlation. (A) RV insertion points LGE, thought to correspond to inter-
stitial fibrosis in histology. (B) Interstitial fibrosis (increased synthesis of collagen and extracellular matrix components, without evidence of myocyte
loss) Masson’s trichrome, ×40. (C) Intramural LGE, within the LVH segments, thought to correspond to replacement fibrosis in histology. (D) Re-
placementfibrosis (increased interstitial collagen with evidence of myocyte loss). Masson’s trichrome×40. (B,D) Courtesy:Homem Gouveia R, MD,
PhD, Portugal. (A,C) Courtesy: Ferreira A, MD and Marques H, MD, Hospital da Luz, Lisbon, Portugal.
Figure 10 LGE and native T1 map in a patient with HCM. The LGE image (left) shows enhancement in the anterior wall that is also seen on the T1
map. The T1 map (right) shows an additional high signal in the inferior septum. Images courtesy of Dr Rina Ariga, Prof. Stefan Neubauer, University of
Oxford Centre for Clinical Magnetic Resonance Research.
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patients may also result from pseudo-normalization of systolic volu-
metric indexes. Indexed stroke volume is often reduced in HCM due
to the small LV cavity typical of this disease.
Doppler myocardial imaging (DMI) and 2D-speckle tracking
echocardiography (2D-STE) overcome some of these pitfalls. The
assessment of systolic function in HCM is possible and reproducible
with DMI, if standardization and adequate acquisition planes are
performed.92 By the use of DMI, HCM patients show low annular
and regional LV systolic velocities in both hypertrophic and non-
hypertrophic segments and increased systolic asynchrony.93 – 97
Moreover, a systolic (s′) velocity of ,4 cm/s at the lateral mitral
annulus was shown to be an independent predictor of worse prog-
nosis and a marker of occult severe LV systolic dysfunction and
disease progression.95,96 Another study associated systolic asyn-
chrony (intraventricular delay between six basal segments longer
than 45 ms) with an increased risk of ventricular arrhythmias and
SCD.97
Colour DMI-derived strain and strain rate have also been
used,98– 100 but this Doppler method is limited by angle dependence
and low reproducibility. Moreover, these measures of regional de-
formation are affected by translational global heart motion and by
tethering from adjacent segments.
2D-STE provides a direct measure of myocardial strain, independ-
ently of the insonation angle, assessing circumferential, radial, and
longitudinal functions, as well as rotational/twist mechanics.101 –104
Table 6 EACVI expert consensus key points on MMI
assessment of anatomy in HCM
1. TTE is the first-line technique for the assessment of anatomy in
patients with HCM.
2. The presence, distribution, and severity of LVH should be
documented in all HCM patients using a common standardized
protocol for all imaging modalities. Measurements of LV wall
thickness should be performed at end diastole and are more
accurate in short-axis views.
3. The systematic assessment of intraventricular obstruction (at rest
and with bedside manoeuvres—Valsalva and standing) and of all the
components of the mitral valve apparatus is mandatory.
4. Exercise echo should be performed in symptomatic patients if
bedside manoeuvres fail to induce LVOTO ≥50 mmHg; in
asymptomatic patients, it may be considered when the presence of a
LVOT gradient is relevant to lifestyle advice and decisions on medical
treatment.
5. CMR with LGE assessment should be performed to provide tissue
characterization (presence, location, type, and extension of
fibrosis) and to accurately document anatomy (WT, mitral valve
apparatus, and mechanism of obstruction and MR when these are
not conclusively defined on echocardiography).
Figure 11 Typical echocardiographic systolic function findings in a patient with HCM. (A) Supernormal ejection fraction (72%). Apical four-
chamber view: end-diastole (left) and end systole (right). (B) The patient has low indexed stroke volume (30 mL/m2). (C) PW-DMI of the IVS:
low systolic (s) myocardial velocity (7 cm/s). (D) 2D-STE—longitudinal strain. Reduced LV longitudinal function (Global longitudinal
strain ¼ 29%). (E) 2D-STE—circumferential strain. The average LV systolic circumferential strain is only slightly reduced (219.5%), whereas
some segments have clearly reduced function. PW-DMI, pulsed wave Doppler myocardial imaging.
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As early signs of LV systolic dysfunction, HCM patients show a
decrease in regional and global longitudinal strain (LS), before the
impairment of LVEF. Additionally, a decreased septal and regional
LS (higher than210%) hasbeen related to susceptibility for ventricu-
lar arrhythmias in HCM.105
Other studies have correlated the occurrence and magnitude
of strain to the presence and extent of fibrosis,76,106,107 suggesting
that 2D-STE may be more accurate than CMR in its detection.83
However, the role of 2D-STE in the detection of total and specific
types of fibrosis, as well as its prognostic implications, needs
further clarification76 in larger sample sizes of HCM patients.
Global and regional circumferential strain, dependent on mid-wall
fibres, may be reduced in HCM, reflecting mid-wall disease involve-
ment. However, circumferential strain analysis has yielded inconsist-
ent results in HCM, because it may be either decreased (as a
consequence of mid-wall circumferential fibres involvement) or
increased (as a compensatory mechanism for early longitudinal im-
pairment). Rotational mechanics is also abnormal in HCM. Though
the extent and amplitude of rotation and twisting is usually normal,
its direction is sometimes abnormal and LV twist time is often pro-
longed.108 However, because of their suboptimal feasibility, LV rota-
tion and twist mechanics are not yet ready to be used in clinical
practice.
3D echo provides potential further insights on LV function in
HCM, showing good correlations with CMR.51 3D-STE is also a
promising tool, but not yet shown to be useful in HCM.
Cardiac magnetic resonance
CMR provides a reproducible and reliable quantification of LVEF in
HCM and may help in the assessment of LV function, whenever
image quality is suboptimal with echo or in the presence of atypical
variants.53
It might also be useful in the assessment of regional function, using
myocardial tagging, but this technique has not yet found wide clinical
application.109,110
As stated above, the presence . . . presence and extent of fibrosis
has been related to progressive LV dilatation and LV systolic dysfunc-
tion in HCM,18 and the prediction of evolution to LV systolic dysfunc-
tion seems to depend on the extension of LGE in terms of percentage
(.10%) of LV mass.
Cardiac CT
CCT may provide an accurate assessment of LV volumes and EF,
but data on its application in HCM are lacking and its use is limited
by radiation.
Cardiac nuclear imaging
Though LVEF assessed by RA was shown to be accurate and repro-
ducible in HCM,111 its routine application for the sole purpose of
EF assessment is nowadays not needed, given the accuracy and avail-
ability of echo and CMR.
LV diastolic function
HCM is classically defined as a ‘diastolic disease’ and the hallmark of
diastolic HF.112 – 115
Echocardiography
TTE is the technique of choice for assessing LV diastolic function in
HCM. However, this evaluation is difficult and complex,116 –119
reflecting the multifactorial nature of LV diastolic dysfunction in
this condition.
No single non-invasive echo Doppler parameter has been vali-
dated to be completely accurate in the assessment of LV filling pres-
sures (LV-FP) in HCM. Remarkably, the transmitral inflow profile
shows weak correlations with invasive measurements and should
not be used alone to quantify LV-FP in HCM.116,117 However, the
difference between the duration of atrial reverse wave of the pul-
monary venous flow Ar and the duration of transmitral A wave
(Ar-A ≥ 30 ms) seems to be associated with elevated LV-FP in
HCM.119
Moreover, two other parameters—LA dilation and PHT—can in-
directly reflect increased LV-FP in HCM.119 2D echo LA volume
indexed to body surface area (LAVI, mL/m2, in the four-chamber
view) is a simple and mandatory parameter31 to assess diastolic func-
tion in HCM patients. It provides long-term information of the chron-
ically elevated LV-FP, particularly in the absence of significant MR and
AF. Moreover, LAVI predicts exercise capacity in non-obstructive
HCM and when ≥34 mL/m2 it is associated with increased LV-FP,
HF, AF, and increased mortality in HCM.31,120,121
With the systematic use of LAVI, the classical flow and volumetric
methods of assessment of LA function122 –124 have lost clinical im-
portance. However, strain analysis of the LA is gaining popularity.
2D-STE shows that LS of the LA is reduced in all three atrial
phases.122 The most studied parameter is the LA peak strain during
the reservoir phase (corresponding to LV systole).122 In another
2D-STE study,125 LA dysfunction represented the main correlate of
HF symptoms in HCM.
LV early diastolic function is abnormal in HCM, and several DMI
studies have shown126,127 reduced early diastolic myocardial velocity
(e′), in segments with and without hypertrophy. Septal e′ was also
found to be an independent predictor of ventricular arrhythmias
and death in children with HCM.95
The role of pulsed DMI in the assessment of LV-FP in HCM is
controversial, as the correlations between the E/e′ ratio and LV-FP
found in one study117 were not confirmed.118 Despite these findings,
the E/e′ ratio has been correlated with exercise tolerance in
HCM.50,95
In accordance with the EAE/ASE recommendations,119 we
suggest a comprehensive and integrated four criteria approach to
assess high LV-FP in HCM: E/e′ ≥ 10,117 Ar-A ≥ 30 ms, LAVI
≥34 mL/m2, and systolic pulmonary artery pressure (PAPs)
.35 mmHg (Figure 12).
The role of 2D-STE on the assessment of diastole is promising,
and preliminary studies with small sample sizes have shown a
delayed and prolonged LV untwist, extending beyond the initial
25% of diastole108 and low apical reverse rotation.128 However,
the feasibility of 2D STE-derived twist and untwist is in general
poor. The assessment of diastolic LS is also promising in HCM.
Cardiac magnetic resonance
CMR allows the assessment of mitral inflow/pulmonary vein profiles
and annular velocities. However, the value of these measurements
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has not been validated in HCM. Posterior wall (PW) velocity using
phase-contrast CMR shows that HCM patients have increased
aortic stiffness (higher in patients with LGE) that correlates adversely
with exercise capacity, independently of LV morphology, diastolic
function and LVOT obstruction.127,129,130
Cardiac CT
There are no convincing data on the usefulness of CCT in this setting
in HCM and it is rare to need CCT with this aim.
Cardiac nuclear imaging
Due to the wide availability of echo, RA is not any longer used to
assess diastolic function. However, time-honoured studies showed
that RA could assess diastolic filling in patients with HCM. Peak
filling rate (PFR) and the time to PFR were the most commonly mea-
sured parameters. Using RA, improvement in diastolic function has
been shown with verapamil.131 Gated single photon-emission com-
puted tomography (SPECT) myocardial perfusion imaging was also
used to assess LV diastolic function111 (Table 7).
Figure12 Typical echocardiographic DF findings in a young male 31-year-old patient with HCM. (A) Two-dimensional apical four-chamber view:
severe LV hypertrophyand LA dilatation, with an increased LAvolume index (.34 mL/m2). (B) Transmitral Doppler flow pattern. (C) Pulsed DMI of
the lateral annulus: reduced Em wave, with inverted Em/Am ratio; E/e′ ... 10. (D) Tricuspid regurgitation velocity (TRV), with evidence of
increased estimated systolic pulmonary pressures (Courtesy of Dr Pacileo G. et al.). LV, left ventricle; E, transmitral early filling wave; A, transmitral
atrial contraction wave; Sm,peak systolic velocity; Em, early diastolic wave; Am, late diastolic wave.
Table 7 EACVI expert consensus key points on MMI
assessment of myocardial function in HCM
1. Echocardiography is the first-line technique to assess systolic and
diastolic function in HCM.
2. The assessment of systolic function should include conventional
data (EF, FS, and indexed stroke volume) and recent parameters
(longitudinal LV function with DMI and 2D-STE). The 2D-STE
assessment of LV systolic radial and circumferential function as well
as rotational and twist mechanics are currently not recommended
as clinical but as research tools.
3. Diastolic parameters should include lateral E/e′ , Ar-A, LAVI and
PAP. Isolated transmitral inflow patterns and grades should not be
used to quantify LV FPs. The 2D-STE assessment of diastolic
function (LV and LA) is still a research tool.
4. CMR with LGE assessment is recommended in HCM in this setting
as the presence and extent of replacement fibrosis has been related
to progressive LV dilatation and systolic dysfunction in HCM.
5. Nuclear imagingmethods and cardiac CT have limited indications in
the assessment of systolic and diastolic function in this disease.
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Figure 13 Functional imaging of ischaemia: dipyridamole stress echo in a HCM patient without epicardial CAD. Left—PWD flow of the medial
LAD at rest. Right—PWD flow of the same artery and segment during high-dosage dypiridamole. The increase in velocity from rest to stress is 1.7
(reference range .2): low CFR due to microvascular dysfunction, associated with worse outcome.
Figure14 Functional imaging of ischaemia with CNI: SPECT (Tc-99m-Sestamibi in a 34-year-old male patient with HCM with historyof chest pain
in the absence of epicardial CAD). Stress (upper row) and rest (lower row). The figure apparently shows a fixed, non-reversible defect (scar) in the
basal segments of the LV, with a non-coronary artery distribution. The apical perfusion is normal. However, this pattern may be a false perfusion
defect due to increased hypertrophic midventricular and apical uptake of the radiotracer. Courtesy: Raposo L, MD, Hospital da Luz, Lisbon, Portugal.
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The detection of myocardial
ischaemia and the assessment of
myocardial metabolism and
beta-adrenergic receptors
Myocardial ischaemia in the absence of epicardial CAD is common in
HCM132 and may be responsible for symptoms and complications of
this disease.132 –134 As stated above, the pathophysiological cascade
of microvascular ischaemia causing myocyte necrosis, followed by re-
placement fibrosis and LV remodelling with systolic dysfunction, is ra-
tional and conceptually attractive, explaining the natural history of
some HCM patients.
Thus, ischaemia assessment in HCM adds an incremental value to
the clarification of symptoms, to risk stratification and definition of
prognosis.21 However, its routine assessment is often neglected
and remains controversial.
Myocardial ischaemia: functional
imaging
Echocardiography
Decreased coronary flow reserve (CFR), related to coronary micro-
vascular dysfunction,135 is a major mechanism for ischaemia in
HCM.136
CFR, assessed by TTE using PWD sampling of the left anterior des-
cending artery (LAD), is often decreased in HCM patients with or
without symptoms,137 and an abnormal CFR (CFR ,2) is a strong
and independent predictor of unfavourable outcome137 (Figure 13).
Additionally, the concomitant presence of epicardial CAD may
contribute to ischaemia.138 Stress echo139 with dual echo imaging
(regional wall motion analysis and induced CFR on the LAD using
high-dosage dipyridamole, 0.84 mg/kg iv in 6 min) or adenosine is
useful in the distinction between epicardial CAD and microvascular
ischaemia. Patientswith epicardial CAD showreducedCFR and indu-
cible wall motion abnormalities, whereas patients with isolated cor-
onary microcirculatory damage show reduced CFR without wall
motion abnormalities.139
The role of EE in the assessment of wall motion abnormalities in
HCM patients is controversial, but in one study140 it was predictive
of adverse outcomes.
Cardiac magnetic resonance
Pharmacological stress CMR (with vasodilators) confirms, with ex-
cellent spatial resolution, that HCM patients have blunted myocardial
blood flow in hypertrophied and non-hypertrophied segments,
greater in the subendocardium.35 CMR also provides insights
between the pathophysiology of ischaemia by matching areas of ab-
normal perfusion with morphological abnormalities such as LVH
Figure 15 Functional imaging of ischaemia with nuclear imaging techniques:PET. Stress dipyridamole (upper row) and rest (lower row)
13NH3 perfusion PET images in an 14-year-old girl with HCM IVS 29 mm. Stress: LV dilation and subendocardial hypoperfusion (IVS and
antero-lateral wall). Rest: increased IVS 13NH3 uptake is seen, indicative of IVS hypertrophy. Courtesy of Prof. Roberto Sciagra`, University
of Florence, Italy and of I. Olivotto, Florence, Italy.
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Figure 16 Non-invasive coronary angiography (CCT). Anatomical imaging of epicardial CAD in a 52-year-old patient with HCM and chest pain.
Left—apical HCM. Centre and right—moderate-to-severe stenosis of the first diagonal branch of the LAD (arrows).
Figure 17 Non-invasive coronary angiography (CCT). Anatomical imaging of the epicardial coronary arteries in a patient with HCM and chest
pain. Top row—Myocardial bridging of the medial segment of the LAD. Lower row—volumetric reconstructions of the same individual, in systole
and in diastole. Courtesy of Gonc¸alves P, MD, PhD, Hospital da Luz, Lisbon, Portugal.
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and LGE.141 However, data on the prognostic impact of this features
are still missing.
Cardiac CT
At the present time, CCT has no role in the functional assessment of
ischaemia in HCM.
Cardiac nuclear imaging
ThoughSPECT is not afirst-line test to assess myocardial ischaemia in
HCM, this method is, in some centres, requested to detect ischaemia
in this disease.
SPECT myocardial perfusion imaging (using Thallium-201 and
Tc-99 m labelled tracers) often shows the presence of reversible
and fixed defects (suggesting ischaemia and scar), even in the
absence of epicardial CAD.142 Thus, a positive SPECT study in
HCM has a relatively low PPV for epicardial CAD detection and a
negative study high NPV for epicardial CAD. The presence of ischae-
mia and scarring has been associated with worse prognosis (adverse
remodelling, overt-systolic dysfunction, syncope arrhythmias, and
SCD).133 The relief of obstruction post-myectomy was associated
Table 8 EACVI expert consensus key points on MMI
assessment of myocardial ischaemia in HCM
1. The assessment of myocardial ischaemia is an important but often
forgotten topic inHCMand its assessment remains controversial. In
patients with chest pain of uncertain aetiology, and for
determination of prognosis, myocardial ischemia may be
investigated with functional and/or anatomical imaging tests.
2. For functional imaging of ischaemia, PET or CMR myocardial
perfusion imaging under vasodilators stress may be used.
Alternatively, stress echocardiography CFR assessment of the LAD
with concomitant wall motion analysis provides diagnostic and
prognostic information and may allow the distinction between
obstructive epicardial CAD and microvascular ischaemia.
3. Cardiac CT plays a role in the anatomical assessment of the
epicardial coronary arteries in HCM (bridging, epicardial CAD, and
before ASA)
4. For studying pathophysiological processes related to ischaemia,
metabolism, myocardial receptors and innervation, nuclear imaging
techniques may be useful, though their routine clinical use is not
recommended.
Figure 18 Surgical myectomy monitoring with intraoperative TOE, 08. Upper row—before surgery: IVS hypertrophy, mitral SAM (arrow) (left),
colour aliasing in the site of obstruction (LVOT) and SAM-related MR (right). Lower row—after myectomy and after weaving from cardiopulmonary
bypass pump before chest closure: reduction of WT in the basal septum, no mitral SAM (left), no turbulence in the LVOT and minimal residual MR
(right). TOE, transesoephageal echocardiography; LA,left atrium; RA, right atrium. Courtesy: Silva F, MD, Hospital da Luz, Lisbon, Portugal.
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with improvement or with normalization of perfusion.143 However,
careful interpretation of the images is needed, because areas with
hypertrophy appear much brighter (higher uptake and counts),
leading to false-positive diagnosis of ischaemia in non-hypertrophied
segments2,111,144,145 (Figure 14).
Proton emission tomography (PET) imaging (using N-13 labelled
ammonia and O-15 labelled water) has been used to measure
absolute myocardial blood flow in patients with HCM. In opposition
to SPECT, PET allows the direct quantification (in mL/min/gr) of
myocardial blood flow (Figure 15) and is the most reliable non-
invasive quantitative method for assessing myocardial ischaemia in
HCM.27 Despite PET generalization is still limited by the high cost
of cameras and radiotracers, the invaluable information provided
by this technique will in the future contribute to spread its use in
clinical practice.
Myocardial perfusion PET studies in HCM patients without epicar-
dial CAD have shown that myocardial blood flow may be normal at
baseline, but the increase in response to pharmacological vasodila-
tion maybe significantly blunted,34,35,146,147 with an adverse prognos-
tic impact.146,148
Stress perfusion PET with dipyridamole show selective subendo-
cardial ischaemia that improves with verapamil.35
Anatomical imaging of the coronary
arteries
Anatomical imaging of the coronary arteries in HCM is usually per-
formed with invasive coronary angiography, but CCT is used in spe-
cialized centres.
Myocardial bridging is an inborn abnormality with an intramural
course of an epicardial artery, usually the mid-segments of the
LAD.149–151 Its precise prevalence in the general population is
unknown, varying from 0.5 to 16% on angiography and a recent
autopsy study showed that it is very common in HCM (41% of
patients).152 Sincecoronarybloodflow isderivedduringdiastole,myo-
cardial bridging is often asymptomatic, but because of the systolic
‘milking effect’ of the coronary artery, angina, acute myocardial infarc-
tion, arrhythmias, and SCD have been described. As a usually benign
condition, routinescreening formyocardialbridging is notappropriate.
Cardiac CT
In the presence of unclear chest pain, CCT is useful to evaluate the
presence of epicardial CAD in patients with intermediate probabil-
ity153 –156 (Figure 16).
CCT is also accurate in the assessment of bridging157,158
(Figure 17), allowing to perform dynamic imaging by reconstructing
the vessel diameters in diastole and in systole.159
Though invasive coronary angiography remains the most indicated
technique, another possible indication of CCT in HCM may be the
assessment of coronary anatomy, especially if an interventional treat-
ment, e.g. alcohol septal ablation (ASA), is planned.2,160
Cardiac magnetic resonance
Studies on the assessment of the origin and proximal segments of
epicardial coronary arteries in HCM are lacking.
Imaging of metabolism, myocardial
receptors, and innervation
Though still mostly investigational, CNI and CMR are powerful re-
search tools in this topics, looking for a clear role in clinical practice.
Echocardiography
Echo has currently no role in the assessment of metabolism in HCM.
Figure 19 Cine CMR-SSFP four-chamber view—HCM patients with severe obstruction, NYHA class 3 despite maximal medical treatment. The
echocardiogramwasnot completely conclusiveon the pathophysiologyof obstruction. Left—apical insertion of aPM (yellowarrows) as the cause of
obstruction, determinant in the option of gradient reduction therapy (mitral valve apparatus surgical reconstruction and neither myectomy nor
ASA). Centre—non-contiguous LVH and anterior displacement of PMs to the anterior wall (blue arrows). Images courtesy of Dr Rina Ariga,
Prof. Stefan Neubauer, University of Oxford Centre for Clinical Magnetic Resonance Research. Right—multiple groups of PMs of different location
shape and size (red arrows). NYHA, New York Heart Association.
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Cardiac magnetic resonance
Some studies have demonstrated impaired myocardial energy me-
tabolism using 31P MR spectroscopy,161,162 irrespective of the
degree of hypertrophy.162
Cardiac CT
CT is not useful in this setting in HCM.
Cardiac nuclear imaging
CNI plays a key role in this topic. SPECT imaging using I-123-beta-
methyl-p-iodophenylpentadecanoic acid (BMIPP) can assess fatty
acid metabolism and I-123-BMIPP myocardial uptake seems
decreased inHCM,especially in the subendocardiumofhypertrophic
segments.163,164
PET with F-18-fluorodeoxyglucose (FDG) and C-11-acetate, re-
spectively, for glucose and oxidative metabolism assessment has
shown impairment in oxidative and glucose metabolism, mainly in
the hypertrophic myocardium.165
PET imaging has also been used to assess autonomic dysfunction in
HCM patients, that show normal plasmatic concentrations of cathe-
colamines but increased local catecholamine levels due to impaired
neurotransmitter reuptake into the nerve terminals, leading to
decreased myocardial b-adrenoceptor density.166
Myocardial innervation was also found to be abnormal, using
I-123-metaiodobenzylguanidine (I-123-MIBG) with SPECT and
C-11-hydroxyephedrine with PET.167,168
Further studies are needed to relate changes in metabolism, myo-
cardial receptors and innervation to ischaemia, fibrosis and to the
heterogeneous phenotypic expression and prognosis seen among
HCM patients (Table 8).
Monitoring of non-invasive and
invasive therapeutic procedures
Medical treatment
Imaging plays a major role in the assessment of the effects of medical
therapy in HCM patients.
Echocardiography
Echo (at rest and exercise) is widely used in the assessment of efficacy
of medical treatment169,170 in LVOTO and in the evaluation of the
effects of experimental agents on morphology and function, both
in animal and clinical studies.171
Cardiac magnetic resonance
CMR may be considered in the case of suboptimal echo data.
Cardiac CT
CCT may be useful in the case of suboptimal echo images or CMR is
contraindicated.
Cardiac nuclear imaging
In the past, RA and non-imaging scintillation probe have been used to
assess the effects of verapamil on LV systolic and diastolic dysfunction
and on exercise tolerance in patients with HCM.131,172
Surgical myectomy and mitral surgery
MMI has an important role in the periprocedural assessment of HCM
patients undergoing myectomy, with or without associated mitral
surgery.
Figure 20 Intracoronary MCE in the selection of patients for ASA. Patient (A) (left)-selective opacification of the basal IVS, close to the contact
lesion (yellow arrows), no perfusion of remote segments/walls. This patient underwent ASA. Patient (B) (right)—mild opacification of the basal IVS
with opacification of undesired remote segments in the inferior and posterior walls (red arrows). ASA was not performed, Courtesy:
Dr A. Hagendorff, Leipzig, Germany. MCE, myocardial contrast echocardiography.
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Echocardiography
Intraoperative TEE (Figure 18) plays a key role in surgery, assessing:
(i) The mechanisms of LVOTO: anatomical definition of the LVOT,
of the mitral valve apparatus, and of the IVS (WT, location of the
impact lesion, distance of maximum WT to the aortic annulus,
and apical extent of the septal bulge).
(ii) The amount—extension, width, and depth—of the myocar-
dium to be removed (usually higher than in ASA, extending
from the point of anterior mitral leaflet–septal contact
upwards to the base of the right coronary cusp and downwards
to the apex, if necessary).
(iii) The mechanisms of MR (determinant of the type of mitral
surgery).
(iv) The immediate results after weaning from cardiopulmonary
bypass pump, before chest closure.173
(v) Early complications (ventricular septal defect or aortic regurgi-
tation, when myectomy occurs too close to the right coronary
cusp or due to direct leaflets injury).174,175
Cardiac magnetic resonance
CMR provides unique detailed anatomical information on the deter-
minants of LVOTO, specifically of all the elements of the mitral valve
apparatus, that may contribute to obstruction and may require repair
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 10 Echocardiography in HCM
Indications Major
advantages
Major disadvantages
1. First-line
method in all
HCM
patients
Widely available/
repeatable
Suboptimal image quality
(patient’s acoustic
window-dependent)
2. Real-time interpretation
operator-dependent
3. Inexpensive
4. No radiation,
usually no
contrast
HCM, hypertrophic cardiomyopathy.
Table 9 EACVI expert consensus key points on MMI in
monitoring non-invasive and invasive treatment
procedures in HCM
1. Echocardiography is recommended in all patients undergoing
medical and invasive treatment. Intraoperative TOE is mandatory
during cardiac surgery and intracoronary MCE is mandatory during
ASA.
2. The role of CMR is increasing when gradient reduction therapy is
considered (surgical myectomy or ASA), providing detailed
anatomical and pathophysiological information on the mechanism
of LVOT obstruction and/or of MR, with impact on the choice of
procedure (surgery vs. ASA) and on the type of surgery (valve
replacement vs. repair of leaflets, chordae, PMs).
3. CT can be used to evaluate the anatomical distribution of the septal
arteries before ASA. Moreover, CT is a suitable alternative when
echocardiographic images are inadequate and CMR is
contraindicated.
4. Routine nuclear imaging for the assessment of therapeutic
procedures (non-invasive and invasive) is not recommended in
patients with HCM. Nuclear testing may be performed when there
are technical limitations, non-availability or contraindications for
echocardiography, CMR, or cardiac CT.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 11 CMR in HCM
Indicationsa Major
advantages
Major
disadvantages
1. Fibrosis/LGE
assessment
Excellent
spatial
resolution
Specific metallic
medical devices/
foreign bodies may
contraindicate
CMR
2. Anatomical
assessment before
invasive gradient
reduction therapy
(surgery vs. ASA, in
the case of
surgery—type)
Excellent
temporal
resolution
Claustrophobia may
limit CMR use
3. Differential diagnosis
(phenocopies)
Excellent
contrast to
noise ratio
Adverse reactions to
contrast agents
(rare)
4. Complementing echo
(especially, in the
case of suboptimal
echo images)
Fibrosis (LGE
and T1
mapping)
CMR, cardiac magnetic resonance; HCM, hypertrophic cardiomyopathy.
aShould be considered at least once in all HCM patients and repeated if clinically
needed.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 12 Cardiac CT in HCM
Indications Major
advantages
Major
disadvantages
1. Epicardial CAD Excellent spatial
resolution
Radiation
2. Myocardial bridging Coronary
arteries
Low temporal
resolution
3. Septal arteries pre-ASA No standardized
protocols
4. Suboptimal echo images
and CMR
contraindicated
Iodated contrast
use
ASA, alcohol septal ablation; CMR, cardiac magnetic resonance.
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or resection.176 –178 In recent years, the importance of preoperative
CMR to guide surgical planning has been progressively increasing
(Figure 19).61,179,180
Cardiac CT
It provides similar information to CMR when this technique is contra-
indicated.
Cardiac nuclear imaging
201-Tl-SPECT may assess the impact of myectomy on myocardial
perfusion: the majority of patients show normalization or improve-
ment of myocardial perfusion and a small number of patients
acquire new fixed defects.143
Alcohol septal ablation
Echocardiography
2D echo is useful in patient selection for ASA (IVS WT between 18
and 25 mm). During the procedure, the use of MCE (intracoronary
injection—in a septal perforator branch of the LAD—of an echo
contrast agent with saline) is mandatory, determining whether
the selected branch to occlude supplies the ‘target site’ of
SAM—septal contact, without opacifying the ‘non-target un-
desired’ remote territories (lateral wall, apex, RV, and PM)
(Figure 20). This technique is usually performed with TTE in multiple
views, conventional and off-axis, though TEE may also be an option.
The use of MCE increases the likelihood of success and reduces
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 13 CNI in HCM
Indications Major
advantages
Major
disadvantages
1. Myocardial perfusion
(ischaemia/scar)
Perfusion Radiation
2. Differential diagnosis with
phenocopies
Metabolism,
receptors,
innervation
Low spatial
resolution
3. Metabolism, receptors
and innervation
Low temporal
resolution
4. Suboptimal echo images,
CMR contraindicated,
CCT non-available
CMR, cardiac magnetic resonance; CCT, cardiac computed tomography; CNI,
cardiac nuclear imaging.
Figure21 HCMin thenon-hypertrophic/early phenotypephase. (A) 2DTTE, long-axis parasternal view—mitral valvedysplasia, no LVH. (B) Low DMI
myocardial s′ (6 cm/s) ande′ (5 cm/s) velocities. (C)Mildly reduced/borderlineregional longitudinal strain in several segments (between212and215%).
(D) Cine CMR, SSFP, two-chamber view—exuberant myocardial crypts in the inferior wall (in daily clinical practice crypts are often more subtle).
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fluoroscopy time, the amount of ethanol used, the infarct size, and
the incidence of atrio-ventricular block and remote myocardial in-
farction.181 – 185
Echo Doppler is also important in the immediate evaluation of
LVOTO and MR reduction, and also in the long-term follow-up in-
cluding MCE in the late assessment of perfusion after ASA.181– 185
Cardiac magnetic resonance
Because of its high signal-to-noise ratio and spatial resolution,
LGE-CMR is the gold standard method for detecting the location
and volume of the infarcted area. In ASA, it is usually located in the
basal septum (lower than in myectomy) and must not reach the RV
side of the inferior IVS.186
Additionally, cine CMR shows the long-term effects of ASA in LV
remodelling, with a reduction in LV mass (average of 10%), mainly in
the IVS but also in remote regions.187 –189 The reduction in LV mass
was observed between 1 week and 1 year after ASA.189,190
Routine CMR after ASA is not recommended, but it can be useful
when LV function and remodelling cannot be satisfactorily assessed
with echo, or when gradients recur late after the procedure.36
Cardiac CT
Because of its limitations (lower contrast-to-noise ratios than CMR,
less standardized acquisitions, and radiation exposure),191,192 CCT is
notafirst-linemethodafter ASA.Nevertheless, itmaybeanalternative
when echo images are suboptimal, or when CMR is contraindicated.
Moreover, beforeASA, CCTmayevaluate the anatomical distribu-
tion of the septal arteries and the mechanism of LVOTO.193,194 After
an unsuccessful ASA, CT can evaluate the patency of the septal
arteries and the extent of necrosis, assessing the chances of
success of a second procedure. The CCT volumes of hypo- and
hyperenhancement areas correlate with CMR, though CCT tends
to overestimate hypoperfused areas and total infarct size.191,195
Cardiac nuclear imaging
CNI is rarely used in clinical practice after ASA. Gated SPECT LVEF
usually does not change after ASA,196,197 and phase analysis has
shown that LV dyssynchrony improved in the subset of HCM patients
who had septal activation delay and LV mechanical dyssynchrony at
baseline.144
SPECT perfusion studies after ASA showed fixed defects in the
basal and midseptum in the vast majority of patients (96.7%) that,
in another study, significantly decreased in size over time.144
Dual-chamber pacing
The contemporary role of dual-chamber pacing (DCP) in gradient
reduction in HCM is controversial.
Echocardiography
During implantation, TTE may be exceptionally needed to confirm
apical RV lead position or to exclude perforation. After the proced-
ure, it may be helpful to assess the reduction in LVOTO and the in-
crease in LV filling.
Later, echo is important in pacing optimization, selecting the best
A–V delay, according to the PWD transmitral inflow and/or aortic
flow analysis.198
Cardiac resonance imaging
As CMR compatible pacing systems are increasingly becoming avail-
able, the role of CMR will certainly increase in the future.
Figure 22 Profile SCD: MMI in the assessment of maximal WT in HCM by echo (left), CMR (centre), and CCT (right).
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Cardiac CT
CT may be rarely useful, only in the case of suboptimal echo images
and non-CMR compatible pacing systems.
Cardiac nuclear imaging
At the present time, CNI has no clinical indications in this field.
However, after DCP in HCM, CNI has shown decrease of stress
thallium-201 perfusion defects and more homogeneous PET
N-13-ammonia myocardial perfusion reserve197 (Table 9).
Integrated MMI in HCM
MMI techniques are complementary to face several clinical problems
of HCM (Tables 10–13).
MMI in family screening and in preclinical
diagnosis
TTE is the first-line imaging modality for clinical screening in first-
degree relatives (Figure 21). Between 10 and 21 years old, yearly
screening is recommended, and in adults, periodic screening
should be performed every 5 years, as late-onset hypertrophy
can occur.36,199
The criteria for the detection of HCM in these individuals include
low cut-off values and a WT of.13 mm in the anterior septum and/
or in the posterior LV wall is suggestive of HCM.43
Though several small studies have observed functional and mor-
phological abnormalities in G+ patients in the absence of LVH,
none is consistently present and none has reliably been linked with
the development of LVH or with clinical outcome.
In the absence of LVH, some individuals show minor mitral
valve abnormalities (dysplasia, prolapse, incomplete SAM, chordal
elongation, laxity, and hypermobility).42 Several DMI studies also
have shown the presence of reduced s′ and e′ velocities before the
onset of LVH,200 and one201 found that a lateral s′ ,13 cm/s had a
sensitivity of 100% and a specificity of 93% for differentiating the
G+ individuals without LVH fromthe controls. This impaired region-
al longitudinal myocardial function,202 as well as abnormal apical
rotation,203 were later described with 2D-STE.
Figure 23 Novel SCD risk prediction model: role of imaging (in this case echocardiography). Of the eight pre-specified predictor variables
assessed at baseline evaluation related to SCD risk at 5 years, half are derived from imaging: (A) Maximal wall thickness; (B) fractional shortening
(not included in the final risk prediction model); (C) LVOT obstruction (peak gradient 89 mmHg), please note the “dagger- shaped” envelope;
(D) Left atrium dimensions in left parasternal view.
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Though these abnormalities do not establish the diagnosis of
HCM, they are useful in identifying gene carriers, leading to closer
follow-up. The limitations include the absence of large studies con-
firming cut-off values and the low specificity in older individuals
(aging and coexisting diseases may change velocities and strain).
Moreover, their predictive value is unknown: given the incomplete
disease penetrance, subjects with abnormal findings may never
develop the classical phenotype (low PPV). On the other hand, the
presence of normal data does not exclude the later development
of LVH (low NPV). Of consequence, the prognostic impact of
normal and abnormal myocardial velocities or strain in G+ patients
without LVH remains controversial.
CMR should be considered in the case of suboptimal echo
images, borderline or doubtful echo data, in high-risk families
when the diagnosis of HCM is still in doubt but would have direct
implications on management (implantation of ICD or exclusion
from competitive sports),36 or when the electrocardiogram
(ECG) becomes abnormal and the echocardiogram is normal.
CMR may improve the diagnosis of HCM by detecting LVH
unrecognized by echo and providing additional morphological and
functional data: mitral valve abnormalities, myocardial crypts
(narrow, deep invaginations within the LV myocardium, often in
the inferior IVS),204,205 false tendons running parallel to IVS,206
reduced segmental peak systolic circumferential strain, and peak dia-
stolic circumferential strain rate and regional fibrosis.207,208
Again, none of these abnormalities is specific of HCM, limiting its
clinical usefulness.
MMI in the approach according to clinical
evolution profiles (SCD,209 HF,210 and
AF stroke120)
Profile SCD
In the classical stratification model, echo is useful in the detection of
massive LVH (.30 mm) (Figure 22), a conventional risk factor for
SCD,37,81,211 and in the assessment of a number of non-conventional
Figure24 MMI in HCM, classical phenotype [echocardiography: (A) asymmetrical septal hypertrophy, mitral SAM, mild-to-moderate LA dilation;
(B) SAM-related MR and turbulence in the LVOT]. CMR—(C) apical 4C, cine CMR, SSFP-midventricular hypertrophy, and obstruction, small apical
aneurysm. (D) LGE-CMR with concomitant intramural and RV insertion points LGE. CardiacCT—(E) two-chamber view, severe hypertrophy of the
anterior wall and (F ) short-axis view: LVH involving both the anterior wall and the anterior IVS. Nuclear SPECT perfusion imaging—bottom row—
increased tracer uptake in apical and midventricular hypertrophic walls, fixed basal circumferential defect (scar vs. false defect, see text).
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risk factors (LV aneurysms, LVOTO,212 LA dilation, LV systolic dys-
function, and low DMI velocities).
In a recent SCD risk prediction model,38 eight pre-specified pre-
dictor variables were assessed at baseline evaluation, allowing the es-
timation of SCD risk at 5 years. Remarkably, four out of eight are
derived from echocardiography (maximal WT, fractional shortening
(not included in the final risk prediction model), LA diameter, LV
outflow gradient), strengthening the crucial role of imaging in SCD
risk prediction (Figure 23).
Because of its higher spatial resolution, CMR should be used when
echocardiographic data are either non-diagnostic or doubtful, espe-
cially in the correct quantification of WT and in the detection of small
apical aneurysms. Additionally, CMR provides unique information on
the presence, location type, and extension of fibrosis, a possible risk
factor for SCD in HCM.
CCT is only indicated if echo data are suboptimal or CMR has con-
traindications. Though CNI tests do not play a major role in this topic,
in specific patients, in whom ischaemia is suspected to play a major
role, they may provide additional information.111
Profile ‘HF’ and the natural history of HCM
A broad phenotypic evaluation of HCM patients has been recently
proposed23 to define the natural history of HCM. Accordingly,
each member of the HCM population belongs to one of the following
sequential patterns: (i) non-hypertrophic stage and early phenotype;
(ii) ‘classical phenotype’ (Figure 24); (iii) adverse remodelling; (iv)
overt dysfunction (previously ‘burnt out’ or ‘end stage’). This last
advanced ‘hypokinetic stage’ has two different morphological
types: the restrictive type (more frequent, still with some residual
ASH, small LV with severediastolic dysfunction and mild or moderate
systolic dysfunction); and the dilated type (more rare, dilated LV, no
LVH, severe systolic dysfunction, and high left ventricular filling pres-
sure) (Figure 25).
Though far from perfect and requiring refinements and incre-
mental information, specifically in LV-systolic function (incorpor-
ation of DMI and 2D-STE longitudinal function data) and in LV
diastolic function (reducing the importance of isolated transmitral
inflow as an index of diastolic dysfunction), this classification repre-
sents a valid working model of a rational and integrated MMI ap-
proach to HCM patients.
Profile AF/stroke
HCM patients have a four-fold increased risk to develop AF that
affects 20% of these individuals.36
In this profile, the assessment of LA remodelling (dilation and dys-
function) is essential. Echo remains the first-line method in assessing
the LA, as the prognostic impact of an LAVI of .34 mL/m2 is well
known.36 Recent studies with 2D-STE have shown reduced LA
strain values in the three phases of LA function (reservoir, conduct,
and pump) in HCM patients, but the clinical value of these parameters
still has to be confirmed (Figure 26).
ThoughCMRand CCT(excellent spatial resolution) aswell asCNI
(functional information) may assess the LA, they are seldom used in
this setting.
MMI and differential diagnoses with
phenocopies
Several diseases may cause the ‘LVH phenotype’ and their diagnosis
may lead to specific treatment, with prognostic impact. MMI techni-
ques are complementary in this setting.
Figure 25 MMI in HCM, overt dysfunction phase. Top: Hypokinetic restrictive form (A) TTE, apical four- chamber view—concentric moderate
LVH, small LV cavity, LA dilation. (B) Transmitral inflow profile—restrictive pattern. (C) SPECT perfusion—mild reversible circumferential defect in
medial LV segments, (D ) cine CMR-SSFP, four-chamber view. Bottom—hypokinetic dilated form in aHCM patient. (A′) TTE, long axis left parasternal
view, no hypertrophy, LVand LA dilation. (B′) M-mode, fractional shortening 20%. (C′) StressPET perfusion, severe septal and anterior wall ischaemia
with ischaemia-induced LV dilation. (D′) Cine CMR-SSFP, four-chamber view. TTE, transthoracic echocardiography.
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Amyloid heart disease is a good example of the complementary
role of the different imaging techniques in the differential diagnosis
with HCM (Table 14 and Figure 27).
The discrepancy between ECG (no LVH criteria or low-voltage
QRS) and echo (LVH) is suggestive of cardiac amyloidosis (CA). Typ-
ically, CA patients show moderate LVH, ‘sparkling’ myocardial
texture, valvular thickening, RV free wall, and interatrial septum
hypertrophy (loss of physiological interatrial septal echo
drop-out), pericardial effusion, and, in early stages, ASH with
LVOT obstruction.213 Regional and global diastolic dysfunction are
early features in CA, and global systolic dysfunction a late finding.
DMI shows low systolic and diastolic velocities and a recent
2D-STE study described relative apical sparing in CA.214
However, at early stages, other imaging techniques may be
useful.215 CNI, using 99mTc-DPD scintigraphy [specifically in trans-
thyretin (TTR)-related amyloidosis—senile and familial], is an
inexpensive and useful technique, as TTR is avid for 99mTc-DPD, in
opposition to sarcomeric HCM.
CMR also provides useful information in CA216 showing a highly
specific pattern of global or segmental subendocardial LGE, with
similar myocardial and blood pool gadolinium kinetics (similar T1).
T1 mapping is also promising in CA.
217
In hypertensive heart disease, maximal WT rarely exceeds
15 mm (except in blacks, in the presence of renal failure and excep-
tionally in elderly HT patients). In HT, LVH is usually concentric or
mildly asymmetric, sometimes with a ‘sigmoid IVS’ or with
mild-to-moderate basal septum hypertrophy (a IVS/PW thickness
ratio of .1.5 and/or an unusual distribution of hypertrophy
suggest HCM).218
Though LVOT obstruction points to HCM, it may be seen in HT,
particularly in the case of significant basal hypertrophy. Associated
structural anomalies of the mitral valve apparatus suggest HCM.
Figure 26 AF—stroke clinical profile in a 52-year-old patient with HCM, paroxystical AF and embolic stroke. Left—TTE, apical four-chamber
view: LA dilation; right—2D-STE: LA deformation parameters in the same patient– low LA longitudinal strain values in all the three phases of
atrial function (reservoir, conduct and pump). Courtesy of Ros¸ca M, MD, Bucharest, Romania.
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Table 14 The eight EACVI MMI criteria to differentiate HCM from cardiac amyloidosis
Imaging data HCM Cardiac amyloidosis
Echo, CMR, CCT
LVH Severe, asymmetric Moderate, concentric, ‘sparkling’
LVOTO Frequent Rare (may exist in early stages)
Pericardial effusion Rare Frequent
IAS hypertrophy Rare Frequent
Apical sparing Rare Frequent
CMR
LGE RV insertion points, intramural Diffuse, subendocardial (global or segmental)
T1 mapping Under research Work in progress; typical patterns
CNI
99mTc-DPD uptake No Yes (TTR—senile and familial)
HCM, hypertrophic cardiomyopathy; CMR, cardiac magnetic resonance; CCT, cardiac computed tomography; Echo, echocardiography; CNI, cardiac nuclear imaging; LVH, left
ventricular hypertrophy.
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Figure27 MMI in a 79-year-old individual with cardiac amyloidosis. (A) TTE, apical 4C view—LVH with sparkling texture, IAS hypertrophy, peri-
cardial effusion, LA dilation, normal/reduced LV cavity. (B) Transmitral inflow—restrictivepattern. (C) DMI—lowmyocardial velocities (s′, e′, and a′).
(D ) Cine CMR, SSFP, short-axis view—concentric tough mildly asymmetric LVH. (E) Global subendocardial LGE, with similar myocardial and blood
pool gadolinium kinetics ((similar T1), highly specific of amyloidosis. (D,E) Courtesy of Ferreira A, Hospital da Luz, Lisbon, Portugal. (F ) Increased
uptake of 99mTc-DPD, a scintigraphic feature specific of TTR-related amyloidosis (senile and familial). In opposition to sarcomeric HCM, TTR is
specifically avid for 99mTc-DPD. (F) Courtesy: Rapezzi C, MD, PhD, Italy. DMI, Doppler myocardial imaging; TTR, transthyretin; DPD, dipho-
sphono-1,2-propanodicarboxylic acid.
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Table 15 The seven EACVI MMI criteria to differentiate HCM from hypertensive heart disease
Imaging data HCM Hypertensive heart disease
Echo, CMR, CCT
LVH Severe, asymmetric, IVS/PW .1.3 (1.5) Moderate (,15 mm—except CRF and blacks),
concentric, or mildly asymmetric IVS/PW,1.3 (1.5)
LVOTO Frequent Rare
‘Sigmoid septum’ Rare Frequent
Severe longitudinal systolic dysfunction Frequent Rare
Inhomogeneity (velocities and strain) High Low
Asynchrony (time intervals) High Low
CMR
LGE Frequent, RV insertion points,
and intramural
Less frequent, non-subendocardial, no specific pattern
HCM, hypertrophic cardiomyopathy; CMR, cardiac magnetic resonance; CCT, cardiac computed tomography; Echo, echocardiography; CNIT, cardiac nuclear imaging tests;
LVH, left ventricular hypertrophy; PW, posterior wall; RV, right ventricle; CRF, chronic renal failure.
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DMI and 2D-STE may help in the differential diagnosis as HT
patients have more homogeneity and synchrony of velocities and
time intervals (in HCM, non homogeneity and asynchrony rule).36
Moreover, HCM patients have more severe longitudinal systolic dys-
function (a LS of ,10% suggests HCM).218
Additionally, while in HT LGE is not so common, mostly non-
subendocardial, with no specific pattern of distribution, it is more fre-
quent and of different types (intramural and in RV insertion points) in
HCM219 (Table 15).
Finally, (Table 13) imaging may be useful in the identification of
many other phenocopies (Anderson–Fabry disease,220 mitochondrial
cytopathies,221 –223 LV non-compaction,224,225 and Noonan syn-
drome,226 among others), providing imaging ‘red flags’ determinant
of the diagnosis; however, their detailed description is beyond the
scope of this document (Table 16).
Future perspectives
In the future, echo will remain the first-line technique in the assess-
ment of HCM patients, but the role of CMR, CCT, and CNI is likely
to increase, providing answers to specific clinical questions unsolved
by echo.
Considering its clinical relevance, imaging-based research on SCD
and on obstruction will certainly continue. However, the assessment
of fibrosis and tissue characterization (for instance with CMR-T1
mapping, with 2D-LGE, integrated backscatter,202,227 and shear-
wave elastography228), of myocardial ischaemia (with CNI-PET and
stress CMR) and of myocardial function, represents imaging future
priorities of HCM imaging.
Accordingly, the correct evaluation of these issues is a major
requisite for the development of tailored and individualized manage-
ment strategies to reverse disease progression and to improve symp-
toms and survival of our HCM patients.
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